Article

A closed, autologous bioprocess optimized for TCR-T cell therapies

2022-07-08

Abstract excerpt

Autologous cell therapy has proven to be an effective treatment for hematological malignancies. Cell therapies for solid tumors are on the horizon, however the high cost and complexity of manufacturing these therapies remain a challenge. Routinely used open steps to transfer cells and reagents through unit operations further burden the workflow reducing efficiency and increasing the chance for human error. Here we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c3d1752b-119d-5c0a-899b-4e41c6ce3017
DOI: 10.22541/au.165727810.00978327/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A closed, autologous bioprocess optimized for TCR-T cell therapiesDOI 10.22541/au.165727810.00978327/v1Read

Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.Semantic proximity Read

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read

High-density microbioreactor process designed for automated point-of-care manufacturing of CAR T cellsSemantic proximity Read

Automated, scaled, transposon-based production of CAR T cellsSemantic proximity Read

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read

Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.Semantic proximity Read

Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.Semantic proximity Read

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.Semantic proximity Read

Towards a commercial process for the manufacture of genetically modified T cells for therapySemantic proximity Read

Development of Ingenui-T, a Novel Vein-to-Vein Solution for Rapid Autologous CAR T-Cell Manufacturing Starting From Whole Blood, for the Treatment of Autoimmune DiseasesSemantic proximity Read

Large Scale In-House Point-of-Care Manufacturing of Clinical Grade Autologous Anti-CD19 CAR T Cells in Saudi ArabiaSemantic proximity Read

Optimized Multiple Amplification Protocol for the Production of Allogeneic Human Vγ9Vδ2 T Lymphocytes for Adoptive Cell Transfer ImmunotherapySemantic proximity Read